Organogenesis Holdings Inc. (ORGO)
NASDAQ: ORGO · Real-Time Price · USD
4.660
-0.110 (-2.31%)
At close: Jul 30, 2025, 4:00 PM
4.660
0.00 (0.00%)
After-hours: Jul 30, 2025, 4:00 PM EDT

Company Description

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States.

The company’s advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM) scaffolds; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic foot ulcers (DFU); Dermagraft, a dermal substitute grown from human dermal fibroblasts to treat DFUs; NuShield, a dehydrated placental allograft and surgical barrier to provide a protective barrier and ECM scaffold to support native healing; PuraPly Antimicrobial (AM) and PuraPly SX, which are antimicrobial barriers for the management of open wounds in surgical settings; and CYGNUS Dual, a dual-layered amniotic tissue graft used to treat chronic and acute wounds.

It also provides PuraPly MZ, a micronized version of PuraPly for the management of open wounds in surgical settings; FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; TransCyte, a bioengineered tissue scaffold that promotes burn healing; and PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications.

In addition, the company develops ReNu, a cryopreserved suspension, which is in Phase 3 trial, for the management of symptoms associated with knee osteoarthritis; and placental products.

It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician offices through direct sales representatives and independent agencies.

Organogenesis Holdings Inc. is headquartered in Canton, Massachusetts.

Organogenesis Holdings Inc.
Organogenesis Holdings logo
CountryUnited States
Founded1985
IndustryDrug Manufacturers - Specialty & Generic
SectorHealthcare
Employees869
CEOGary Gillheeney

Contact Details

Address:
85 Dan Road
Canton, Massachusetts 02021
United States
Phone781 575 0775
Websiteorganogenesis.com

Stock Details

Ticker SymbolORGO
ExchangeNASDAQ
Stock TypeCommon Stock
Share ClassClass A Shares
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001661181
CUSIP Number68621F102
ISIN NumberUS68621F1021
SIC Code2834

Key Executives

NamePosition
Gary S. Gillheeney Sr.President, Chief Executive Officer, Chair of the Board
David C. FranciscoChief Financial Officer
Patrick BilboChief Operating Officer
Lori H. Freedman B.A., Esq., J.D.Chief Administrative and Legal Officer
Brian GrowChief Commercial Officer
William R. Kolb CPASecretary
Robert CavorsiVice President of Strategy

Latest SEC Filings

DateTypeTitle
Jun 26, 2025SCHEDULE 13D/AFiling
Jun 24, 20258-KCurrent Report
May 12, 2025ARSFiling
May 12, 2025DEF 14AOther definitive proxy statements
May 8, 202510-QQuarterly Report
May 8, 20258-KCurrent Report
Apr 29, 2025PRE 14AOther preliminary proxy statements
Apr 29, 202510-K/A[Amend] Annual report
Mar 27, 20258-KCurrent Report
Mar 17, 2025144Filing